# A Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of KMRC011

> **NCT03585803** · PHASE1 · COMPLETED · sponsor: **Intron Biotechnology, Inc.** · enrollment: 26 (actual)

## Conditions studied

- Acute Radiation Syndrome

## Interventions

- **DRUG:** KMRC011 5μg or Placebo
- **DRUG:** KMRC011 10μg or Placebo
- **DRUG:** KMRC011 15μg or Placebo
- **DRUG:** KMRC011 20μg or Placebo
- **DRUG:** KMRC011 25μg or Placebo

## Key facts

- **NCT ID:** NCT03585803
- **Lead sponsor:** Intron Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-11
- **Primary completion:** 2019-09-11
- **Final completion:** 2019-11-28
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2021-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03585803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03585803, "A Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of KMRC011". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03585803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*